HC Wainwright & Co. Maintains Buy on Astria Therapeutics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on Astria Therapeutics (NASDAQ:ATXS) but lowers the price target from $20 to $18.
October 12, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Astria Therapeutics' price target has been lowered from $20 to $18 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The news is directly about Astria Therapeutics. The lowering of the price target might indicate a slightly less optimistic outlook for the company's stock, but the maintained 'Buy' rating suggests that the analyst still sees potential for the stock's growth. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100